

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Ibrutinib with venetoclax for untreated chronic
lymphocytic leukaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During scoping consultation, a consultee highlighted an urgent need for access to novel treatments for younger, fitter patients with chronic lymphocytic leukaemia as currently only fludarabine, cyclophosphamide and rituximab (FCR) or venetoclax plus obinutuzumab via the Cancer Drugs Fund is available to them. This has been addressed by committee because ibrutinib plus venetoclax has been recommended for everyone with untreated chronic lymphocytic leukaemia.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No other issues identified

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other issues identified

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

No equalities issues were relevant for this appraisal. Please see section 3.21.

Approved by Associate Director (name): Ross Dent

Date: 23/03/2023